The National Pharmaco Vigilance Advisory Committee has prohibited the sale and manufacture of the drug Valdecoxib, indicated for arthritis and The National Pharmaco Vigilance Advisory Committee ...
Rofecoxib and valdecoxib have been withdrawn from the market because they increase the risk of cardiovascular events. To determine whether these drugs and other types of selective cyclooxygenase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback